However, it is worth noting that the development of DYRK1A inhibitors may be beneficial in the treatment of other diseases, including neurological disorders such as Alzheimer’s Disease(AD), Parkinson’s and Huntington’s diseases, Down Syndrome (DS) [79] and cancer [20]. Here, DYRK1A is linked to early-onset autosomal dominant Alzheimer disease.